retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide (RETA) is one of

Wellorithm (the platform) is a technology company that facilitates connections between patients and licensed healthcare professionals

A 2024 study led by Wang, Volkow, and colleagues examined two cohorts totaling over 682,000 individuals with either obesity or type 2 diabetes and found the risk of new alcohol use disorder diagnoses was about 50% lower among those taking semaglutide compared to other anti-obesity or diabetes medications (Wang et al., 2024a)

The FDA has stated plainly: "There are no FDA-approved GLP-1 patches." If you can buy it without a prescription, it is not an actual GLP-1 drug

Tirzepatide has been recently added to incretin-based AOM

Aging Cell (2013) 12(2):292302

Gastroparesis / Stomach Paralysis One of the most alarming complications linked to GLP-1 medications is gastroparesis, also known as stomach paralysis